Relmada Therapeutics, Inc. regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2).
The Company's shares maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days, achieving this on September 12, 2025.
Nasdaq confirmed the compliance, allowing Relmada to remain listed and traded on the Nasdaq Capital Market under the ticker "RLMD."
Compliance Regained
Relmada met the minimum bid price requirement after maintaining $1.00 closing bid price for 10 consecutive business days.
Full Compliance Achieved
The Company is now in full compliance with all Nasdaq continued listing requirements, ensuring its stock remains listed on Nasdaq.
Focus on Innovative Therapies
Relmada Therapeutics is dedicated to developing transformative therapies for oncology-related and central nervous system conditions, with lead candidates NDV-01 and sepranolone in mid-stage clinical development.
- Relmada's compliance with Nasdaq's minimum bid price requirement eliminates the risk of delisting, providing stability and confidence to investors and stakeholders.
- The Company's focus on innovative therapies in oncology-related and central nervous system conditions positions it for potential growth and future success in the biotechnology sector.
Relmada Therapeutics' successful compliance with Nasdaq's requirements demonstrates its commitment to transparency and accountability, solidifying its position in the market.